检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:吴敏 李正阳 孟杰 叶惠平 WU Min;LI Zhengyang;MENG Jie;YE Huiping(Department of Otolaryngology,The Affiliated Hospital of Guizhou Medical University,Guiyang 550000,Guizhou,China;Department of Otolaryngology,Guizhou Provincial People's Hospital,Guiyang 550002,Guizhou,China;Department of Otolaryngology,The Affiliated Hospital of Zunyi Medical University,Zunyi 563000,Guizhou,China)
机构地区:[1]贵州医科大学附属医院耳鼻咽喉科,贵州贵阳550000 [2]贵州省人民医院耳鼻咽喉科,贵州贵阳550002 [3]遵义医科大学附属医院耳鼻咽喉科,贵州遵义563000
出 处:《山东大学耳鼻喉眼学报》2025年第2期152-157,167,共7页Journal of Otolaryngology and Ophthalmology of Shandong University
摘 要:大约有3/4的鼻咽癌(nasopharyngeal carcinoma, NPC)患者确诊时已处于中晚期。放射及化学疗法是当前NPC的主要疗法,但部分患者的治疗效果并不理想,NPC的分子机制尚不明确。程序性细胞死亡是由一细胞多种主动有序的死亡方式,在生命活动的平衡中发挥着至关重要的作用。近来的研究发现了程序性细胞死亡与NPC相关,铜死亡、铁死亡、焦亡、自噬、坏死性凋亡、细胞凋亡等多种程序性细胞死亡方式在NPC的不同时期发挥着重要作用。本文将概述细胞的铜死亡、铁死亡、焦亡、自噬、坏死性凋亡和细胞凋亡的分子机制和其在NPC发展中的作用,为探索NPC的发病机制和潜在的治疗靶点提供新的视角。About 3/4 of patients with nasopharyngeal cancer are diagnosed at an intermediate to advanced stage.Radiation and chemotherapy are the main therapies for NPC.However,the treatment efficacy is not always ideal.The molecular mechanism of NPC remains unclear.Regulated death comprises a variety of active and orderly modes of cell death,and is vital in the balance of life activities.Recent studies have associated regulatory death with NPC.Various modalities of programmed cell death,such as cuproposis,ferroptosis,pyroptosis,autophagy,necroptosis,and apoptosis,play important roles in different NPC stages.This article provides an overview of the molecular mechanisms of cupropopsis,ferroptosis,pyroptosis,autophagy,necroptosis,and apoptosis in cells and their roles in NPC development.The information could provide a new perspective for studies exploring the pathogenesis and potential therapeutic targets of NPC.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.33